A-share chemical and pharma stocks surge; Hong Kong biotech jumps 40% on EU drug nod
On September 21, A-share indices rose with the Shanghai Composite up 0.55% and ChiNext up 0.93%, reclaiming 3,400 points. The basic chemicals sector surged as domestic crude oil futures dropped over 7%, lowering costs. Pharmaceutical stocks also hit daily limits. In Hong Kong, Yingpai Pharmaceutical-B surged over 40% after the European Medicines Agency's CHMP recommended approval of its ovarian cancer drug Sepalna.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
A-Share Chemical and Medical Stocks Surge; Crude Oil Drop Boosts Sectors
On September 21, A-share markets rose with the Shanghai Composite up 0.55% and the ChiNext up 0.93%, returning above 3,400 points. The medical and chemical sectors led gains, with multiple stocks hitting daily 20% limits. Huaren Pharmaceutical surged on a 340,000-lot buy order. The chemical sector rallied as domestic crude oil futures plunged over 7%, falling from above 800 yuan/barrel to just over 700 yuan/barrel. Market analysts attributed the chemical rally to lower input costs from falling oil prices. In Hong Kong, the Hang Seng Index traded mostly higher, with biotech firm Yingpai Pharmaceutical-B surging over 40% after the European Medicines Agency's CHMP recommended approval of its ovarian cancer drug Sepalna®. Other notable gainers included China Biologic Products, CSPC Pharmaceutical, and Innovent Biologics. Real estate, beauty care, and building materials sectors also advanced.
Read sourceA-Share Chemical and Pharmaceutical Stocks Surge; Hong Kong Biotech Firm Soars 40%
On September 21, A-share markets rose with the Shanghai Composite up 0.55% and the ChiNext Index gaining 0.93% to reclaim 3,400 points. The pharmaceutical and biomedical sector led gains, with Huaren Pharmaceutical hitting the 20% daily limit on over 340,000 buy orders, and multiple other biotech stocks also surging. The basic chemicals sector also rallied sharply, driven by a more than 7% intraday drop in domestic crude oil futures, which analysts said lowers costs for some chemical sub-sectors. In Hong Kong, Yingpai Pharmaceutical (InxMed) surged over 40% after the European Medicines Agency's CHMP recommended approval of its ovarian cancer drug Sepalna (senaparib), pending final EU Commission decision. Other sectors such as real estate, beauty care, and building materials also posted gains.
A-Share Chemical and Pharma Stocks Surge; Hong Kong's Yingpai Pharma Jumps 40%
On September 21, A-share markets rose, with the Shanghai Composite up 0.55% and the ChiNext Index up 0.93% to above 3,400 points. The basic chemicals sector surged, driven by a sharp drop in domestic crude oil futures (down over 7% intraday), which analysts said lowers costs for some chemical firms. Stocks such as Jindan Technology and Shuangxing New Material hit daily limits. The pharmaceutical sector also saw a wave of limit-up moves, with Huaren Pharmaceutical jumping 20% on over 340,000 buy orders. In Hong Kong, the Hang Seng Index traded mostly higher. Yingpai Pharmaceutical-B surged over 40% after announcing that the European Medicines Agency's CHMP recommended approval of its ovarian cancer drug Sepalna (senaparib) for EU marketing authorization, pending final European Commission decision.
Read sourceShow 2 older updatesHide older updates
A-Share Market Rises; Pharma and Chemical Sectors Surge, Hong Kong Stock Jumps
On September 21, A-share major indices rose, with the Shanghai Composite up 0.55% and the ChiNext Index up 0.93%, returning above 3,400 points. The pharmaceutical and biomedical sector saw a surge, with stocks like Huaren Pharmaceutical and Novogene hitting daily limits. The basic chemicals sector also rallied, driven by falling crude oil prices, which the market believes lower costs for some chemical industries. Domestic crude oil futures fell over 7% intraday, dropping from above 800 yuan/barrel to just over 700 yuan/barrel. In Hong Kong, the Hang Seng Index traded mostly higher. Shares of Yingpai Pharmaceutical-B surged over 40% after the company announced that the European Medicines Agency's CHMP recommended approval of its drug Sepalna for maintenance treatment of advanced ovarian, fallopian tube, and primary peritoneal cancers. The drug will now be submitted to the European Commission for final approval.
Read sourceChemical Sector Sees Limit-Up Surge; Hong Kong Stock Yingpai Pharma Jumps 40% on EU Drug Nod
On September 21, A-share market indices rose, with over 4,300 stocks gaining. The Shanghai Composite rose 0.55%, the Shenzhen Component rose 0.57%, and the ChiNext Index rose 0.93%, briefly returning above 3,400 points. The basic chemicals sector was a major highlight, with multiple stocks hitting the daily limit-up. The article attributes the sector's strength to falling domestic crude oil futures, which dropped over 7% intraday, lowering costs for some chemical companies. Separately, Hong Kong-listed Yingpai Pharmaceutical-B surged over 40% after announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for its drug Sepalna (senaparib) for maintenance treatment of advanced ovarian, fallopian tube, and primary peritoneal cancers. The drug, a self-developed PARP1/2 inhibitor, was approved in China in January 2025 and included in the national medical insurance catalog in December 2025. The article is sourced from Securities Times.
Read source